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Squamous cell carcinoma (SCC) of the lung is the
second most common subtype of lung cancer. With
limited treatment options, the 5-year survival rate of
SCC is only 15%. Although genomic alterations in
SCC have been characterized, identifying the alter-
ations that drive SCC is critical for improving treat-
ment strategies. Mouse models of SCC are currently
limited. Using lentiviral delivery of Sox2 specifically
to the mouse lung, we tested the ability of Sox2 to
promote tumorigenesis in multiple tumor suppressor
backgrounds. Expression of Sox2, frequently ampli-
fied in human SCC, specifically cooperates with
loss of Lkb1 to promote squamous lung tumors.
Mouse tumors exhibit characteristic histopathology
and biomarker expression similar to human SCC.
They also mimic human SCCs by activation of thera-
peutically relevant pathways including STAT and
mTOR. This model may be utilized to test the contri-
bution of additional driver alterations in SCC, as well
as for preclinical drug discovery.
INTRODUCTION
Lung cancer is a leading cause of cancer-related deaths in the
United States and worldwide. Squamous cell carcinoma (SCC)
is the second most common type of lung cancer, representing
30% of cases and over 400,000 deaths worldwide each year
(Cancer Genome Atlas Research Network, 2012; Jemal et al.,
2011). Currently, the 5-year survival rate for SCC is approxi-
mately 15%. One of the major problems contributing to treat-
ment failure is a lack of targeted therapies. Targeted therapies
that are effective against adenocarcinoma, the other major sub-
type of non-small-cell lung cancer (NSCLC), are ineffective or
contraindicated for SCC. The current standard of care for SCC
involves surgery when operable, or combination chemotherapy,
usually a platinum doublet, which has a poor response rate
(Oliver et al., 2013). Identification of new therapeutic targets for
SCC requires elucidation of the critical genes and pathways
driving this disease.40 Cell Reports 8, 40–49, July 10, 2014 ª2014 The AuthorsCancer Genome Atlas Research Network (2012) recently
sequenced 178 human SCCs, identifying numerous genetic
alterations that may serve as valuable therapeutic targets. How-
ever, SCC has one of the highest mutation rates of all tumor
types, making it difficult to distinguish ‘‘driver’’ from ‘‘passenger’’
mutations. Some genetic alterations in SCC occur in proteins for
which targeted therapies are available, such as fibroblast growth
factor receptor (FGFR) and phosphatidyl inositol 3-kinase (PI3K)/
AKT. Other potential oncogenic drivers were discovered for
which there are currently no available therapies, such as the tran-
scription factors SOX2, P63, and NRF2 (Cancer Genome Atlas
Research Network, 2012).
Mouse models of adenocarcinoma and small cell lung cancer
(SCLC) have been utilized to understand mechanisms of tumor
initiation, progression, and therapeutic response (Kwon and
Berns, 2013). Genetic models of SCC have only recently been
generated (Ji et al., 2007; Xiao et al., 2013). The combination of
KrasG12D expression and Lkb1 loss in the mouse lung leads
to lung tumors of multiple lineages (adenocarcinoma, mixed
adenosquamous, squamous, and large cell) (Jackson et al.,
2001; Ji et al., 2007).WhileKRAS is commonlymutated in human
lung adenocarcinomas (21%), it is rarely altered in SCC (6%)
(Perez-Moreno et al., 2012). In the mouse lung, KrasG12D ex-
pression alone promotes the exclusive development of lung
adenocarcinomas (Jackson et al., 2001). LKB1 (also known as
serine/threonine kinase 11; STK11), a tumor suppressor impli-
cated in metabolism, cell polarity, and growth control, is lost or
mutated in 5%–19% of human SCCs (Ji et al., 2007; Perez-
Moreno et al., 2012; Shackelford and Shaw, 2009). This suggests
that Lkb1 loss in the KrasG12D/+Lkb1fl/fl model contributes to the
altered spectrum of lung tumor types, including squamous
tumors.
Recently, a kinase-dead IKKa knockin mouse was reported to
develop lung SCCs (Xiao et al., 2013). This discovery followed
other mouse models with loss-of-function IKKa alleles that
developed papillomas and skin SCC (Liu et al., 2012). The
kinase-dead IKKa knockin mice develop spontaneous SCCs of
the lung but also develop tumors in the skin, forestomach, and
esophagus, contributing to early mortality (Xiao et al., 2013).
When wild-type IKKa expression is restored using a skin
promoter, mice survive longer and develop lung SCCs but still
have defects in the forestomach and esophagus. These
phenotypes are consistent with the observation that IKKa is
(legend on next page)
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downregulated in human skin SCC and in head and neck SCC
(Liu et al., 2012), but the role of IKKa in lung SCC is less clear.
Copy number losses and genomic mutations in IKKa are rare
in human lung SCCs, and other mechanisms of altering IKKa
and its related pathways are not well defined (Cancer Genome
Atlas Research Network, 2012). The broad spectrum of lung
tumor types in KrasG12D/+Lkb1fl/fl mice and the extrapulmonary
phenotypes in the kinase-dead IKKamicemake the study of bio-
markers, mechanisms of progression, and squamous-specific
therapies difficult.
SOX2 is one of the most frequently altered genes in human
SCC, amplified in 21% and overexpressed in 60%–90% of tu-
mors (Bass et al., 2009; Brcic et al., 2012; Cancer Genome Atlas
Research Network, 2012; Hussenet et al., 2010). SOX2 is also
frequently expressed in early-stage SCC, suggesting that
SOX2 expression may be an initiating event in SCC development
(Bass et al., 2009; Brcic et al., 2012; Hussenet et al., 2010). Gain-
of-function and loss-of-function studies have previously under-
scored a critical role for Sox2 in lung development, specifically
its importance in the proliferation and differentiation of basal
and neuroendocrine cells (Gontan et al., 2008; Lu et al., 2010;
Que et al., 2009). Consistent with this observation, SOX2 ampli-
fication is common in SCC and SCLC, lung tumors that are
thought to originate from basal and neuroendocrine cells,
respectively (Bass et al., 2009; Hussenet et al., 2010; Rudin
et al., 2012). However, expression of Sox2 alone in the lung pro-
motes hyperplasia and tumors of the adenocarcinoma lineage
with aberrant basal cell marker expression (Lu et al., 2010).
Although SOX2 is one of the most frequent genetic alterations
associated with human SCC, it has not yet been shown to pro-
mote squamous lung tumors in vivo. Here, we sought to identify
combinations of gene drivers that promote lung SCC.
RESULTS AND DISCUSSION
Lentiviral Approach to Identify Combinatorial Drivers of
Lung SCC
To identify genetic combinations that facilitate Sox2-driven SCC,
we used a lentiviral approach to combine Sox2 expression with
loss of distinct tumor suppressor genes. Bicistronic lentiviruses
expressing Sox2 and Cre recombinase are delivered specifically
to the mouse lung using intranasal inhalation, allowing constitu-
tive expression of two genes driven by b-Actin and Pgk pro-
moters, respectively. Lentiviruses are administered to mice
harboring conditional LoxP-flanked (‘‘floxed’’) tumor suppressor
alleles to simultaneously create two genetic ‘‘hits’’: expression ofFigure 1. Lenti-Sox2;Lkb1fl/fl Tumors Express Biomarkers of Human S
(A) Left panels: two representativemicroCT images with tumor outlined in dashed
dimensional microCT reconstructions (3D recon) with lung tumors in blue. Righ
arrows. Mouse IDs (JC156 and JC163) correspond to tumors in Table 1.
(B) Lenti-Sox2;Lkb1fl/fl tumors and human SCC stained with H&E. Top scale bars
(C) Representative KrasG12D/+ mouse lung adenocarcinomas, Lenti-Sox2;Lkb1fl/
represents 50 mM.
(D) Average IHC score based on 0–5 scoring systemwhere 5 indicates >90% posi
and 0 indicates negative. Human SCCs (n = 12), tumors from Table 1, and KrasG1
tumors analyzed is indicated in the color key. Error bars represent mean ± SEM. S
Sox2/Lkb1 versus human SCC.
See also Figure S1.
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using the Cre/LoxP system (Figure S1A). Control cDNA (GFP)
or murine Sox2 were cloned into bicistronic lentiviral vectors
under control of the b-Actin promoter (referred to as Lenti-
GFP-Cre or Lenti-Sox2-Cre, respectively). Sox2 expression
was validated by immunoblot analysis and Cre expression was
verified using a human embryonic kidney 293T (HEK293T) re-
porter system that was used to calculate viral titer (Figures
S1B and S1C).
Mice harboring conditional LoxP-flanked tumor suppressor
alleles (Lkb1fl/fl, p53fl/fl, or p53fl/flRbfl/fl) were infected with Lenti-
GFP-Cre or Lenti-Sox2-Cre. LKB1 is lost or mutated in 5%–
19% of human SCCs, but loss of Lkb1 alone in the mouse lung
does not lead to tumor formation (Ji et al., 2007). TP53 is one
of the most common genetic alterations in SCC (mutated in
81% of tumors), but loss of p53 alone in the mouse lung leads
to rare adenocarcinomas after long latencies (Cancer Genome
Atlas Research Network, 2012; Jackson et al., 2005; Meuwissen
et al., 2003). Both TP53 and RB1 alterations are common in
human SCLC (in which SOX2 is genomically amplified in 27%
of cases), and loss of p53/Rb in the mouse lung leads to SCLC
after long latencies, as well as rare adenocarcinomas (Cancer
Genome Atlas Research Network, 2012; Meuwissen et al.,
2003; Rudin et al., 2012). We reasoned that these tumor sup-
pressor genes may cooperate with Sox2 expression to promote
lung tumor development. Beginning at 3 months postinfection,
mice were monitored for tumor formation every month by
low-dose microcomputed tomography (microCT) imaging for
7.5–12 months or until tumors were detected. The Sox2-Lkb1
combination had the greatest reduction in tumor-free survival
compared to other genetic combinations tested (Figure S1D).
Individual tumors were observed by microCT in all three condi-
tional genetic backgrounds and analyzed by histopathology (Fig-
ures 1A and 1B; Table 1). It is striking that most of the tumors in
the Lenti-Sox2-Cre Lkb1fl/fl combination (n = 7 of 9 tumors in 17
mice) were classified as squamous tumors, as determined by
analysis of hematoxylin and eosin (H&E)-stained sections by
two independent pathologists (Figure 1B; Table 1). Sox2-Lkb1
squamous tumors exhibited characteristic SCC features, in-
cluding keratin pearls and desmoplastic stroma (Brcic et al.,
2012) (Figure 1B). Lkb1fl/fl mice receiving Lenti-GFP-Cre did
not develop tumors (n = 0 of 14 mice) as expected (Table 1).
Sox2 expression in the context of p53 loss or loss of p53/Rb
did not lead to squamous lung tumors, but it did lead to a few
adenocarcinomas at latencies of 5–12 months (Table 1). The
Sox2-Lkb1 combination exhibited significantly increased tumorCC
blue lines and heart outlined in solid red lines in axial view. Middle panels: three-
t panels: gross morphology of dissected lungs with tumors indicated by blue
represent 100 mM; bottom scale bars represent, 50 mM.
fl tumors, or human lung SCCs stained with K5, K14, p63, or TTF1. Scale bar
tive; 4 indicates >75%; 3 indicates >50%; 2 indicates >25%; 1 indicates >10%;
2D/+ adenocarcinomas were compared for K5, p63, and TTF1 IHC. Number of
tudent’s unpaired t test, *p = 0.02 for Sox2/Lkb1 versus Kras, and p = 0.04 for
Table 1. Lenti-Sox2;Lkb1fl/fl Mice Develop Squamous Lung Tumors
Genotype
Virus
delivered
No. of mice
with tumors/
total mice
p value for
tumor
incidence
Sox2 versus
GFP
Mouse
ID with
tumor
Pathological review
based on H&E
(subtype after
biomarker staining)
Biomarker
staining
No. of squamous
tumors/total
tumors (based
on biomarker
staining)
Lkb1
recombination
by PCR Latency
Lkb1fl/fl GFP 0/14 (0%) 0/0 (0%) 6–10
months
Sox2 7/17 (41%) p = 0.009 8/9 (89%) 6–10
months
JC156 squamous K5+, K14+,
p63+, Sox2+,
TTF1 low
Yes 6 months,
5 days
JC156b squamous n/a n/a 6 months,
5 days
JC163 squamous K5+, K14+,
p63+, Sox2+,
TTF1+
Yes 7 months,
15 days
JC163b squamous K5+, K14+,
p63+, Sox2+,
TTF1+
n/a 7 months,
15 days
JC191 squamous K5+, p63+,
Sox2+, TTF1
Yes 7 months,
9 days
JC205 well-differentiated
adenocarcinoma
(squamous)
K5+, p63+,
Sox2+
Yes 7 months,
5 days
JC215 well-differentiated
adenocarcinoma
K5, p63,
Sox2+
Yes 9 months,
8 days
JC217b squamous K5, p63+,
Sox2+, TTF1
n/a 9 months,
12 days
JC229 squamous K5+, p63+,
Sox2+, TTF1
n/a 9 months,
18 days
p53fl/fl GFP 0/10 (0%) 0/0 (0%) 5.5–7.5
months
Sox2 1/8 (11.1%) p = 0.44 0/1 (0%) 5.5–7.5
months
JC147 well-differentiated
adenocarcinoma
K5-, p63,
Sox2-, TTF1+
5 months,
19 days
Rbfl/flp53fl/fl GFP 2/28 (7%) 0/2(0%) 6–12
months
JC118 well-differentiated
adenocarcinoma
n/a 6 months,
6 days
JC204 poorly
differentiated
NSCLC (Adeno)
K5, p63,
Sox2, TTF1+
8 months,
12 days
Sox2 2/14 (14%) p = 0.59 0/3 (0%) 6–12
months
JC189 well-differentiated
adenocarcinoma
K5, p63,
Sox2, TTF1+
10 months,
27 days
JC216 poorly
differentiated
NSCLC (Adeno)
K5, p63,
Sox2, TTF1+
12 months
JC216b poorly
differentiated
NSCLC (Adeno)
n/a 12 months
Detailed histopathology, biomarker staining, Lkb1 recombination results, and latency of tumors are identified inmice receivingGFP orSox2 lentiviruses
in indicated conditional genetic backgrounds. n/a indicates insufficient tissue available for analysis. See also Figure S1.
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incidence (Fisher’s exact test, two sided, p = 0.009) and a signif-
icant enrichment in squamous tumors (89% versus 0%, Fisher’s
exact test, two sided, p = 0.001), compared to all other genetic
combinations combined (Table 1). Together, these findings sug-
gest that Sox2 expression and Lkb1 loss specifically cooperate
to promote squamous tumorigenesis.
Lenti-Sox2-Cre Lkb1fl/fl Tumors Express Biomarkers of
Human SCC
Expression of basal cell markers such as cytokeratin-5 (K5), -14
(K14), and P63 distinguish human SCC from adenocarcinoma
(Reis-Filho et al., 2003; Terry et al., 2010). We analyzed tumors
from each genetic combination, as well as 12 human SCCs for
squamous biomarker expression. Sox2-Lkb1 squamous tumors
consistently expressed all of the basal cell markers examined
(K5, K14, and p63) and were similar to human SCC, whereas
adenocarcinomas in mice from other genetic combinations
including KrasG12D did not (Figures 1C and 1D; Figure S2;
Table 1). Most human lung tumors express TTF1 (also known
as Nkx2.1), but mean expression of TTF1 is significantly reduced
in SCCs compared to adenocarcinomas and is reportedly ex-
pressed in only 10% of SCCs (Perner et al., 2009). Compared
to KrasG12D-driven mouse adenocarcinomas that were uniformly
TTF1 positive, TTF1 levels were significantly reduced in Sox2-
Lkb1 tumors (Student’s unpaired t test, p = 0.02) (Figures 1C
and 1D). Sox2-Lkb1 tumors exhibited a broad spectrum of
TTF1 expression, ranging from no TTF1 expression (similar to
human SCCs) to higher levels of expression. Sox2-Lkb1 tumors
expressed significantly less TTF1 than mouse adenocarcinomas
but significantly more TTF1 than human SCCs (Student’s
unpaired t test, p = 0.04) (Figures 1C and 1D). Taken together,
these results demonstrate that Sox2-Lkb1 tumors highly
resemble human SCC at the level of histopathology and squa-
mous biomarker expression.
Next, we sought to validate Sox2 expression and Lkb1 loss in
mouse squamous tumors. All Sox2-Lkb1 tumors were strongly
positive for nuclear Sox2 expression, similar to 75% of human
SCCs (n = 9 of 12) (Figures 2A and 2B). KrasG12D-driven adeno-
carcinomas and adenocarcinomas arising from other genetic
combinations (p53 or p53/Rb loss) were negative for Sox2 (Fig-
ures 2A and 2B; Figure S2). Given that the same lentiviruses were
used in all experiments, this suggests that there may be a selec-
tive advantage for high Sox2 expression in the context of Lkb1
loss. It is interesting that KrasG12D/+Lkb1fl/fl squamous tumors
had little or no Sox2 expression, suggesting that there may be
Sox2-independent mechanisms of squamous tumorigenesis
(Figures 2A and 2B). Recombination of the Lkb1 allele was deter-Figure 2. Lenti-Sox2;Lkb1fl/fl Tumors Express Sox2 and Exhibit Activat
(A) Representative IHC of Sox2, p4EBP1, and pAMPK in KrasG12D/+ mouse
KrasG12D/+Lkb1fl/fl squamous tumors. Brown/red staining is positive. Scale bar re
(B) Average IHC scores for Sox2 and p4EBP1 from individual tumors indicated
4 indicates >75%; 3 indicates >50%; 2 indicates >25%; 1 indicates >10%; and 0 i
Error bars represent mean ± SEM. Student’s unpaired t test, ****p < 0.001.
(C) PCR validation of Lkb1 recombination in tumor samples from mice indicate
indicated. Actin serves as input control. Mixed 1:1 Lkb1 WT and floxed DNA, Lk
(D) Left panels: representative images of Sox2- and p4EBP1-positive and -negat
antibodies to SOX2 and p4EBP1.
See also Figure S2.mined by PCR analysis on DNA frommacrodissected Sox2-Lkb1
tumors. All tumors examined (n = 5 of 5) demonstrated the pres-
ence of the recombined Lkb1 floxed allele as well as Sox2
expression (Figure 2C; Table 1). Two of nine Sox2-Lkb1 tumors
appeared as adenocarcinomas by H&E, and both tumors ex-
hibited Sox2 expression and Lkb1 recombination; one tumor
expressed basal cell markers and, as such, was reclassified by
pathologists as squamous, whereas the other tumor did not
express K5 or p63 (Table 1). This suggests that Sox2 expres-
sion and Lkb1 loss may not be sufficient for squamous tumori-
genesis in all contexts and/or that this adenocarcinoma
represents an intermediate state that has the potential to trans-
differentiate to a squamous tumor under certain conditions
(Han et al., 2014).
LKB1 phosphorylates and activates adenosine monophos-
phate-activated protein kinase (AMPK), which negatively regu-
lates the mammalian target of rapamycin (mTOR) pathway.
Immunohistochemical (IHC) analysis of Sox2-Lkb1 tumors
demonstrated an absence of phosphorylated AMPK (pAMPK)
and enhanced expression of phosphorylated eukaryotic transla-
tion initiation factor 4E-binding protein 1 (p4EBP1), an mTOR
substrate (Hay and Sonenberg, 2004; Perner et al., 2009), con-
firming activation of the mTOR pathway (Figures 2A and 2B).
The mTOR pathway is frequently activated in human lung
SCCs and represents a potential therapeutic target (Mantripra-
gada and Khurshid, 2013). Indeed, we observed that, of the
human SCCs with strong SOX2 expression (9 of 12), five demon-
strated evidence of mTOR pathway activation as well (55% of
Sox2+ SCCs) (Figure 2D). Altogether, these data reveal that
SOX2 expression and mTOR activity frequently co-occur in
human SCC and that Sox2-Lkb1 tumors strongly resemble
human SCCs at the level of pathway activation.
Sox2-Driven SCCs Exhibit Expression or Activation of
Potential Therapeutic Targets
To identify pathways dysregulated in Sox2-driven SCC, we per-
formed IHC analysis for therapeutically relevant pathways in
Sox2-Lkb1 tumors,KrasG12DLkb1fl/fl squamous tumors identified
by K5 staining, and human SCCs. FGFR family members are
frequently amplified and/or harbor activating point mutations in
human SCC, and FGFR inhibitors are currently in clinical trials
(Cancer Genome Atlas Research Network, 2012; Dutt et al.,
2011; Liao et al., 2013). Notably, SOX2 and FGFR2 expression
are highly correlated in human SCC, and SOX2 can bind the
FGFR2 promoter (Bass et al., 2009; Boyer et al., 2005; Fang
et al., 2011), suggesting that FGFR2 may be a direct target of
SOX2 in lung cancer. We examined expression of FGFR2 inion of the mTOR Pathway Similar to Human SCCs
lung adenocarcinomas, Lenti-Sox2;Lkb1fl/fl tumors, human lung SCCs, and
presents 50 mm.
in Table 1 based on 0–5 scoring system where 5 indicates >90% positive;
ndicates negative. Number of tumors analyzed is indicated in color key at right.
d in Table 1. Wild-type (WT), floxed (flox), and recombined (del) Lkb1 alleles
b1+/+, and Lkb1fl/fl normal lung DNA serve as controls.
ive IHC. Right panels: contingency table of human SCCs (n = 12) stained with
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Figure 3. Murine SCCs Exhibit Expression
of Potential Therapeutic Targets
(A) Representative IHC of KrasG12D/+ mouse lung
adenocarcinomas, mouse Lenti-Sox2;Lkb1fl/fl tu-
mors, human lung SCCs, and KrasG12D/+Lkb1fl/fl
squamous tumors stained with indicated anti-
bodies. Brown/red staining is positive. Scale bar
represents 50 mm.
(B) Average IHC score of FGFR2, pErk, pAkt, and
pStat3 stains in individual tumors from Table 1,
human SCCs, and KrasG12D/+Lkb1fl/fl squamous
tumors. Number of tumors analyzed is indicated in
color key at right. IHC scoring system is based on
scoring system where 5 indicates >75% positive;
4 indicates >50%; 3 indicates >25%; 2 indicates
>10%; 1 indicates >2.5%; and 0 indicates nega-
tive. Error bars represent mean ± SEM. For
Student’s unpaired t test, *** indicates p < 0.0002
and *p < 0.01.
(C) Immunoblot of cytoplasmic (c) and nuclear (n)
protein extracts for SOX2, pStat3, and NF-kB p65
from human lung cancer cell lines under control ()
or 48 hr SOX2 induction (+) in stable Tet-On cells.
Nemo and Parp serve as loading controls for
cytoplasmic and nuclear fractions, respectively.
See also Figure S3.each tumor group and found that Fgfr2 expression tended to be
higher in Sox2-Lkb1 tumors compared to KrasG12DLkb1fl/fl squa-
mous tumors, but these data did not reach statistical signifi-
cance (Figures 3A and 3B). FGFR2 was highly induced by
SOX2 expression in human A549 lung cancer cells harboring
LKB1 mutations (Figure S3) but not in two other cell lines with
LKB1 mutations (H23 and H157) (Mahoney et al., 2009; Fig-
ure S3). We were not able to detect phospho-Frs or pFGFR2 in46 Cell Reports 8, 40–49, July 10, 2014 ª2014 The Authorsthe Sox2-Lkb1 tumors, so it remains to
be determined whether pathways down-
stream of FGFR2 are activated.
The nuclear factor kB (NF-kB) path-
way is activated and implicated in
various cancers, including lung adeno-
carcinoma (Meylan et al., 2009; Xue
et al., 2011) and lung SCC (Xiao et al.,
2013). Sox2-Lkb1 tumors demonstrated
evidence of NF-kB pathway activity
as indicated by nuclear p65, similar
to Kras-driven adenocarcinomas (Fig-
ure S3). Although, the role of NF-kB
signaling in SCC development remains
to be determined, activation of this
pathway in multiple mouse models of
SCC warrants further study of NF-kB
as a potential therapeutic target. Induc-
ible SOX2 expression alone was not
sufficient to increase nuclear p65 in hu-
man cell lines regardless of LKB1 status,
suggesting that other factors are likely
driving NF-kB signaling in these cells
(Figure 3C).The RAS/MAPK/PI3K pathways are frequently activated in
human squamous tumors via different mechanisms (Cancer
Genome Atlas Research Network, 2012). To examine the status
of these pathways, we stained tumors for pErk and pAkt.
Notably, pErk was significantly reduced in Sox2-Lkb1 tumors
compared to KrasG12DLkb1fl/fl squamous tumors and human
SCCs (Figures 3A and 3B). We speculate that Kras activation
in KrasG12DLkb1fl/fl squamous tumors maintains pErk signaling,
which is absent in Sox2-driven tumors. We observed variable
levels of pAkt in Sox2-Lkb1 tumors, ranging from little or no
pAkt to high levels similar to those in KrasG12DLkb1fl/fl tumors
(Figures 3A and 3B). Together, Sox2-Lkb1 tumors had reduced
MAPK pathway activity compared to KrasG12DLkb1fl/fl squamous
tumors, suggesting that Sox2-Lkb1 tumors may rely more
heavily on other growth factor signaling pathways for prolifera-
tion, including mTOR. A recent study published while this article
was under consideration demonstrated that Pten loss cooper-
ates with Lkb1 loss to promote SCC (Xu et al., 2014). Notably,
Pten/Lkb1-null tumors also exhibited low MAPK pathway
activation.
Stat3 has been shown to cooperate with Sox2 to promote
tumor progression in esophageal and forestomach tumors, can-
cers in which SOX2 is genomically amplified (Liu et al., 2013).
Preclinical studies have identified STAT3 inhibitors, and STAT3
decoys are now being tested in patients with head and neck
SCC (Sen et al., 2012). Compared to KrasG12D adenocarcinomas
and KrasG12DLkb1fl/fl squamous tumors, the Jak-Stat pathway
was significantly activated in Sox2-Lkb1 tumors (indicated by
phospho-Stat3) with clear nuclear pStat3 in some cells within
the squamous tumors (Figures 3A and 3B). Human SCCs had
variable levels of pStat3 similar to those in Sox2-Lkb1 tumors
(Figures 3A and 3B). It is striking that, in multiple human lung
cancer cell lines of adenocarcinoma and squamous lineage,
inducible expression of SOX2 consistently promoted nuclear
pStat3 accumulation (Figure 3C). Altogether, these data suggest
that Sox2 contributes to Stat signaling in vivo and thus repre-
sents a therapeutic target warranting further investigation for
SCC treatment.
To summarize, we have used a lentiviral-based approach to
generate a mouse model of SCC based on Sox2 expression
and Lkb1 loss, highlighting their cooperation in lung SCC devel-
opment. Both SOX2 expression and mTOR pathway activity
frequently co-occur in human SCC, making this model particu-
larly relevant to the human disease. Mouse tumors recapitulate
the human disease at the level of histopathology, biomarker
expression, and activation of potential therapeutic targets that
have been largely unexplored in SCC treatment. It is important
to note that Stat signaling was induced by SOX2 in vitro and
enriched in Sox2-driven squamous tumors. This model thus
serves as a preclinical tool to test whether STAT inhibition is ther-
apeutically effective against Sox2-driven SCCs.
The low penetrance of tumor formation in this model may be
due to low lentiviral titer and/or the underlying cell of origin.
Although we recognize that tumor numbers in this study are
low, the paucity of other squamous lung tumor models suggests
that this particular genetic combination is highly relevant. While
this article was under consideration, Xu et al. demonstrated
that Pten/Lkb1 loss promotes squamous lung tumors exclu-
sively, in contrast to Kras/Lkb1 mice, which develop multiple
tumor types (Ji et al., 2007; Xu et al., 2014). It remains unknown
why PI3K activation, as opposed to MAPK, would lead exclu-
sively to squamous tumors in the context of Lkb1 loss, especially
since PI3K pathway alterations also occur in adenocarcinoma
(Ding et al., 2008). We speculate that, since Pten/Lkb1-null
tumors express Sox2, Sox2 may be a critical target of the PI3K
pathway in these tumors.In both Pten/Lkb1 and Sox2/Lkb1 mouse models, inflamma-
tory microenvironment and activation of immune signaling path-
ways appear to distinguish SCC from adenocarcinoma (Xu et al.,
2014). A notable difference between the two models is that ade-
noviruses used in Pten/Lkb1 and Kras/Lkb1 models are thought
to enhance inflammation compared to lentiviruses used here.
These models will serve as preclinical tools for further investiga-
tion of immunotherapy efficacy and function.
It is unclear whether SCCs arise from basal cells or whether
the transforming events promote basal cell differentiation. The
identity of the cell of origin for SCC remains an important
unanswered question. One model suggests that basal cells
serve as the cells of origin because SCCs express basal cell
markers and Sox2 is expressed in basal cells (Que et al., 2009;
Sutherland and Berns, 2010). However, other studies suggest
that Sox2 promotes basal cell fate (Han et al., 2014; Lu et al.,
2010). Recent studies in KrasG12D/+Lkb1fl/fl mice suggest that
type II pneumocyte-derived lung adenocarcinomas can transdif-
ferentiate into SCCs (Han et al., 2014). Given that lentiviruses in
our model may target multiple cell types in the mouse lung, it is
possible that Sox2 expression and Lkb1 loss are capable of
altering cell fate to a squamous-like identity. Given that we
also detected one tumor that appeared as an adenocarcinoma
expressing basal cell markers, we speculate that transdifferen-
tiation may also occur in this model. The lentiviral approach
used here could be adapted to investigate the cell of origin for
Sox2-driven SCCs.
Bicistronic lentiviruses may also be used to test other candi-
date SCC drivers, such as P63 and NRF2, as well as to identify
cooperating genetic events that promote SCC. We expect that
murine squamous tumors will have fewer ‘‘passenger’’ genetic
alterations than human SCC due to lack of carcinogen exposure,
thereby providing a biological filter to identify ‘‘driver’’ genetic
changes in SCC. Beyond lung cancer, findings from this model
may have important clinical implications for other squamous or
SOX2-driven malignancies such as SCLC and brain, esopha-
geal, and oral cancers.
EXPERIMENTAL PROCEDURES
Mouse Breeding and Lentiviral Infections
Mice were housed in an environmentally controlled room according to the
Committee of Animal Care. Lkb1fl/fl mice were purchased from The Jackson
Laboratory. LSL-KrasG12D/+ and p53fl/fl animals were kindly provided by Tyler
Jacks. p53fl/flRbfl/fl mice were generated by Anton Berns (Meuwissen et al.,
2003) and obtained from T. Jacks. Lung tumor tissue from KrasG12D/+Lkb1fl/fl
mice was kindly provided by Reuben Shaw. At 6–8 weeks of age, anesthetized
micewere infectedwith107 infectious units/ml of Lenti-Sox2-Cre orGFP-Cre
lentiviruses or 6.473 107 plaque-forming units of AdCre (University of Iowa) by
nasal instillation as described elsewhere (Jackson et al., 2001). Viruses were
administered in a Biosafety Level 2+ room according to Institutional Biosafety
Committee guidelines.
Lentivirus Production
GFP and murine Sox2 cDNAs were cloned into bicistronic lentiviral vectors ex-
pressing Cre to generate Lenti-Sox2-Cre and Lenti-GFP-Cre plasmids and
confirmed by direct sequencing. 293T cells were transfected with a three-
plasmid transfection system including the lentiviral vector, pCMV-delta-8.2
(Addgene) and pCMV-VSV-G (Addgene). Virus was harvested posttransfec-
tion, concentrated by ultracentrifugation (24,000 3 g), and titered using
HEK293T reporter cells stably expressing a Lox-DsRed2(Stop)-Lox-GFPCell Reports 8, 40–49, July 10, 2014 ª2014 The Authors 47
cassette. Number of cells expressing green fluorescent protein was measured
by flow cytometry and used to calculate titer (infectious U/ml).
MicroCT Imaging
At indicated time points, mice were scanned for 30 s to 2 min under iso-
flurane anesthesia using a small animal Quantum FX microCT (PerkinElmer)
at 45 ym resolution, 90 kV, with 160 yA current. Images were acquired using
PerkinElmer Quantum FX software and processed with Analyze 11.0
(AnalyzeDirect).
Human Tissue
Excess deidentified fresh tissue was obtained with prior patient consent under
approved protocol by the institutional review board (#10924). Institutional
guidelines regarding specimen use were followed.
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